See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Natural Disasters
Social Media
Eid
Tariffs
Donald Trump
US Politics
Artificial Intelligence
Stock Markets
Education
Taxes
Senate
Baseball
Published • loading... • Updated

Evolut Low Risk TAVR Still Chugging Along, Now Halfway to Trial's Finish Line

Summary by MedPage Today
(MedPage Today) -- CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical risk, with the Evolut Low Risk trial now halfway to its goal of 10-year follow-up. In...

4 Articles

All
Left
Center
1
Right
MedPage TodayMedPage Today
Reposted by
Anti-Aging, Acupuncture and Health NewsAnti-Aging, Acupuncture and Health News
Center

Evolut Low Risk TAVR Still Chugging Along, Now Halfway to Trial's Finish Line

(MedPage Today) -- CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical risk, with the Evolut Low Risk trial now halfway to its goal of 10-year follow-up. In...

·New York, United States
Read Full Article
Cardiovascular NewsCardiovascular News

ACC.25: Evolut Low Risk trial shows comparable rates of all-cause mortality and stroke with TAVI and surgery at five years - Cardiovascular News

Michael J Reardon. Photo ©ACC/Zach Boyden-Holmes Latest data from the Evolut Low Risk trial demonstrate a numerically lower rate of all-cause mortality or disabling stroke at five years using the Evolut (Medtronic) transcatheter aortic valve implantation (TAVI) system compared to surgery, alongside strong valve performance and durable clinical outcomes. The findings were presented as late-breaking clinical science at the 2025 American College of…

Read Full Article
stocktitan.netstocktitan.net

5-Year Clinical Data: Medtronic TAVR Outperforms Traditional Surgery with Better Heart Outcomes

New clinical data reveals Medtronic's TAVR system achieved lower cardiovascular mortality and superior valve performance vs surgery in low-risk patients. Full analysis inside.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

stocktitan.net broke the news in on Sunday, March 30, 2025.
Sources are mostly out of (0)

Similar News Topics

Chicago, IL

Chicago, IL

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal